ClinicalTrials.gg
Not yet recruitingNCT07903272TRIlogy-6Updated Nov 4, 2026

A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

A Phase 3 interventional study of Ramantamig and Daratumumab in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Oct 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies in Multiple Myeloma by Johnson & Johnson — 13 open to participants now, 33 under way, 12 of them phase 3. Multiple Myeloma · Johnson & Johnson.

Planned enrollment
2nd of 100
1,000 · median 125
Started
2026
with 5 others
Phase 3
35 of 126
5 open now
Primary completion
2037-01
later than 31 of 32 live
Registered
126th of 126
by date

Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 2nd largest by planned enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 in phase 3, reaches primary completion later than 31 of the 32 other live ones, and was the 126th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 126 studies in Multiple Myeloma by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Multiple Myeloma by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to compare how well Ramantamig plus Daratumumab (ramantamig-D) works compared with a treatment that includes Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd), followed by high-dose therapy, autologous stem cell transplantation (using the participant's own stem cells), and maintenance treatment with Daratumumab and Lenalidomide (DR) in participants with newly diagnosed multiple myeloma (NDMM), a blood cancer affecting plasma cells, who are eligible for transplant.

Read the detailed description

TRIlogy-6 trial is being conducted by 2 sponsors: J\&J (N=325) and EMN (N=675); the combined total of 1000 participants enrolled by both sponsors will be analyzed.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have newly diagnosed multiple myeloma (NDMM) according to the international myeloma working group (IMWG) diagnostic criteria
  • Be considered a candidate for high-dose therapy (HDT) and stem cell transplantation (ASCT) and commit to treatment with transplant. Transplant eligibility will be determined by the investigator per institutional standard of care, consistent with applicable regional guidelines
  • as assessed by central laboratory at screening
  • Have an (ECOG) performance status of 0 to 2
  • Participant must sign an form (ICF)

Exclusion criteria

Exclusion criteria:

  • History of uncontrolled illness, including but not limited to: a. Acute diffuse infiltrative pulmonary disease, b. (COPD) with an (FEV1) less than (\<)50 percent (%) of predicted, c. Moderate or severe persistent asthma within the past 2 years or uncontrolled asthma of any classification, d. Evidence of active systemic viral, fungal, or bacterial infection requiring systemic antiviral, antifungal, or antimicrobial therapy, e. Active disease requiring systemic therapy within 6 months before start of trial intervention. f. Disabling psychiatric conditions (for example, alcohol or drug abuse), severe dementia, or altered mental status, g. Stroke, , or seizure within 6 months prior to randomization, h. Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the national cancer institute (NCI) (CTCAE) version 6.0
  • Received any prior or current systemic therapy or stem cell transplant for any plasma cell dyscrasia, such as, but not limited to, smoldering MM, with the exception of emergency use of a short course of . Participants are allowed corticosteroids not exceeding greater than (>) 160 milligram (mg) of dexamethasone (or equivalent) within 14 days prior to trial intervention
  • Received a strong cytochrome P450 () inducer within 5 half-lives prior to randomization
  • Concurrent use of any agent within 30 days or 5 half-lives of the respective drug/investigational medicinal product (IMP) (whichever is longer) before randomization or currently enrolled in an investigational trial
  • Radiotherapy on measurable soft tissue plasmacytoma(s) is not permitted even in the setting of palliation for symptomatic management. However, if the radiation is given for palliative purposes and the radiation portal covers less than or equal to (\<=) 5% of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Arm A: Ramantamig and Daratumumab (Ramantamig-D)

    Participants will receive subcutaneous (SC) dose of ramantamig-D.

    Drug: Ramantamig · Drug: Daratumumab

  • Active comparator
    Arm B: DVRd+ HDT+ ASCT+ DR

    Participants will receive Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) along with High-Dose Therapy (HDT), Autologous Stem Cell Transplantation (ASCT) and Daratumumab and Lenalidomide (DR) maintenance for 2 years or until progressive disease (PD) or intolerable toxicity whichever occurs first. Participants will have the option to continue lenalidomide and/or daratumumab maintenance therapy beyond 2 years, until PD, at the investigator's discretion and sponsor approval.

    Drug: Daratumumab · Drug: Bortezomib · Drug: Lenalidomide · Drug: Dexamethasone · Drug: HDT+ASCT

Interventions

  • Ramantamig will be administered as subcutaneous (SC) injection.

    Also known as: JNJ-79635322

  • Daratumumab will be administered as SC injection.

    Also known as: JNJ-54767414

  • Bortezomib will be administered as SC injection.

  • Lenalidomide will be administered orally.

  • Dexamethasone will be administered orally or intravenously (IV).

  • DrugHDT+ASCT

    HDT and ASCT will be performed as per standard of care.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the duration from the date of randomization to either confirmed progressive disease (PD) or death, whichever occurs first. PD will be determined according to international myeloma working group (IMWG) response criteria.

    Time frame: Up to approximately 10 years

  2. Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)

    12-month MRD-negative CR is defined as participants who achieve MRD-negative status at 12 months (plus minus \[+-\] 3 months) from randomization, as determined by next-generation sequencing (NGS), prior to PD or subsequent antimyeloma therapy (including autologous stem cell transplantation \[ASCT\]).

    Time frame: Up to approximately 12 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of the participant's death due to any cause. If the participant is alive or the vital status is unknown, then the participant's data will be censored at the date the participant was last known to be alive.

    Time frame: Up to approximately 10 years

  2. Percentage of Participants Achieving 24-Month Sustained MRD-Negative CR

    24-month sustained MRD-negative CR is defined as participants who achieve MRD-negative CR status, as determined by NGS, for at least 24 months without any examination showing MRD positive status in between, and prior to PD or subsequent antimyeloma therapy (including ASCT).

    Time frame: Up to 5 years

  3. Percentage of Participants with Very Good Partial Response (VGPR) or Better

    VGPR or better is defined as participants who achieve VGPR, CR, or stringent complete response (sCR) prior to subsequent antimyeloma therapy, in accordance with the IMWG criteria, during or after the trial intervention.

    Time frame: Up to 5 years

  4. Percentage of Participants with Complete Response (CR) or Better

    CR or better is defined as participants who achieve CR or sCR prior to subsequent antimyeloma therapy, in accordance with the IMWG criteria, during or after the trial intervention.

    Time frame: Up to 5 years

  5. Percentage of Participants with Overall Response (ORR)

    Overall response rate is defined as percentage of participants who achieve partial response (PR) or better prior to subsequent antimyeloma therapy, in accordance with the IMWG criteria, during or after the trial intervention.

    Time frame: Up to 5 years

  6. Percentage of Participants with Overall MRD-Negative CR

    Overall MRD-negative CR is defined as participants who achieve MRD negative status, as determined by NGS, at any time point after randomization and prior to PD or subsequent antimyeloma therapy and who achieve CR or better.

    Time frame: Up to 5 years

  7. Percentage of Participants Achieving 12-Month Sustained MRD-Negative CR

    12-month sustained MRD-negative CR is defined as participants who achieve MRD-negative CR status, as determined by NGS, for at least 12 months without any examination showing MRD positive status in between, and prior to PD or subsequent antimyeloma therapy (including ASCT).

    Time frame: Up to 5 years

  8. Progression-Free Survival 2 (PFS2)

    PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as PD, as assessed by investigator, on the first subsequent line of antimyeloma therapy or death from any cause, whichever occurs first.

    Time frame: Up to approximately 10 years

  9. Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent anticancer therapy will be considered treatment-related regardless of the start date of the event. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.

    Time frame: Up to approximately 10 years

  10. Number of Participants With Adverse Events by Severity

    An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment.

    Time frame: Up to approximately 10 years

  11. Number of Participants with Significant Abnormalities in Laboratory Parameters

    Number of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.

    Time frame: Up to approximately 10 years

  12. Change from Baseline in Health-related Quality of Life (HRQoL), Symptoms and Functioning Using the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Scores

    The MySIm-Q is a disease-specific patient reported outcome (PRO) assessment with established content validity for participants with newly diagnosed multiple myeloma (NDMM). It is included to be complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days" and responses are reported on a 5-point verbal rating scale. Higher scores indicate greater severity/impact.

    Time frame: From Baseline up to approximately 10 years

  13. Change from Baseline in HRQoL, Symptoms and Functioning Using the EORTC QLQ C30 Scale Scores

    The EORTC QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social); 1 global health status scale; 3 symptom scales (pain, fatigue, and nausea/vomiting); 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea); and a single impact item (financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.

    Time frame: From Baseline up to approximately 10 years

  14. Change from Baseline in HRQoL, Symptoms and Functioning Using European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Scores

    The EQ-5D-5L is a self-administered, generic health status measure, consisting of a descriptive system and a visual analogue scale (EQ-VAS). The descriptive system covers 5 dimensions of health (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression), each with 5 levels of severity (no problems, slight problems, moderate problems, severe problems, and unable to perform or extreme problems). Higher scores indicate worse HRQoL.

    Time frame: From Baseline up to approximately 10 years

  15. Time to Worsening in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores

    Time to worsening in HRQoL, symptoms and functioning using the MySIm-Q scale scores will be reported. The recall period is the "past 7 days" and responses are reported on a 5-point verbal rating scale. Higher scores indicate greater severity/impact.

    Time frame: Up to approximately 10 years

  16. Time to Worsening in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores

    Time to worsening in HRQoL, symptoms and functioning using the EORTC-QLQ-C30 scale scores will be reported. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.

    Time frame: Up to approximately 10 years

  17. Time to Worsening in HRQoL, Symptoms and Functioning Using the EQ-5D-5L Scale Scores

    Time to worsening in HRQoL, symptoms and functioning using the EQ-5D-5L scale scores will be reported. The EQ-5D-5L descriptive system covers 5 dimensions of health each with 5 levels of severity with higher scores indicating worse HRQoL.

    Time frame: Up to approximately 10 years

  18. Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the MySIm-Q Scale Scores

    Percentage of participants with meaningful improvement in HRQoL, symptoms and functioning using MySIm-Q scale score will be reported. The recall period is the "past 7 days" and responses are reported on a 5-point verbal rating scale. Higher scores indicate greater severity/impact.

    Time frame: Up to approximately 10 years

  19. Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EORTC-QLQ-C30 Scale Scores

    Percentage of participants with meaningful improvement in HRQoL, symptoms and functioning as assessed by EORTC-QLQ-C30 scale score will be reported. he item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.

    Time frame: Up to approximately 10 years

  20. Percentage of Participants With Meaningful Improvement in HRQoL, Symptoms and Functioning Using the EQ-5D-5L Scale Scores

    Percentage of participants with meaningful improvement in HRQoL, symptoms and functioning using EQ-5D-5L scale score will be reported. The EQ-5D-5L descriptive system covers 5 dimensions of health each with 5 levels of severity with higher scores indicating worse HRQoL.

    Time frame: Up to approximately 10 years

  21. Percentage of Participants Who Report Side Effect Burden as Assessed by the European Organization for Research and Treatment of Cancer Item List (EORTC IL) 46

    The EORTC IL46 consists of a single question that measures global impression of burden due to treatment-related symptoms. The response options range from "not at all" to "very much" on a 4 point scale.

    Time frame: Up to approximately 10 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2037, 120 months later.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 120 months is above that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Oct 29, 2026
StartEst.
Dec 14, 2026
Primary completionEst.
Jan 11, 2037
CompletionEst.
Jan 11, 2037
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 29, 2026
Show all 2 updates
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07903272
Collaborators
European Myeloma Network B.V.
Responsible party
Sponsor
First posted
Oct 29, 2026
Start date
Dec 14, 2026 (estimated)
Primary completion
Jan 11, 2037 (estimated)
Completion
Jan 11, 2037 (estimated)
Last update
Nov 4, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramantamig

Start the discussion